

Maternal Screening, Sequential, Specimen #2, Alpha Fetoprotein, hCG, Estriol, and Inhibin A

Patient: | Date of Birth: | Gender: F | Physician:
Patient Identifiers: | Visit Number (FIN):

Information provided indicates that the patient was exposed to carbamazepine during this pregnancy. Infants who have been exposed to antiepileptic drugs (AEDs) in utero run an increased risk of congenital malformations, including neural tube defects (NTDs). Use of polytherapy with more than one AED appears to be associated with a higher risk of birth defects compared with monotherapy. Based on this information, the risk of neural tube defect is increased 9 times. Genetic counseling is recommended.

Gestational Age Comment:

Section 79-1 of New York State Civil Rights Law requires informed consent be obtained from patients (or their legal guardians) prior to pursuing genetic testing. These forms must be kept on file by the ordering physician. Consent forms for genetic testing are available at www.aruplab.com. Incidental findings are not reported unless clinically significant but are available upon request.

PAPP-A Maternal Compliance Statement: This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Maternal Screen Interpretation Compliance Statement: This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Patient Information Used in Risk Calculations

Maternal Age at Delivery:	31.2 yr
Maternal Weight:	206.0 lbs.
Gestational Age at Draw:	16 wks, 3 days
Number of Fetuses:	Singleton
Maternal Race:	Black
Medication-Dependent Maternal Diabetes:	No
Current Smoker:	No
Family History of Neural Tube Defects:	No
Family History of Aneuploidy:	Yes
Specimen:	Initial sample
Crown Rump Length:	53.3 mm
Sonographer Certification #:	Unknown_number
Sonographer Name:	Unknown, Sonog



Patient:

ARUP Accession: 21-150-109408

Maternal Screening, Sequential, Specimen #2, Alpha Fetoprotein, hCG, Estriol, and Inhibin A

Patient: | Date of Birth: | Gender: F | Physician:
Patient Identifiers: | Visit Number (FIN):

Ultrasound Date: 04-28-21

Reference Information

The following links or information offer complete and up to date information about this test, including access to ARUP Consult™ disease topics and other supplemental resources.

- [Maternal Screening, Sequential, Specimen #2, Alpha Fetoprotein, hCG, Estriol, and Inhibin A](http://ltd.aruplab.com/tests/pub/3000148)
(http://ltd.aruplab.com/tests/pub/3000148)
- [Prenatal Aneuploidy Screening](https://www.aruplab.com/genetics/tests/prenatal)
(https://www.aruplab.com/genetics/tests/prenatal)
- [Additional Technical Information](http://ltd.aruplab.com/Tests/Pdf/311)
(http://ltd.aruplab.com/Tests/Pdf/311)



Patient:

ARUP Accession: 21-150-109408